Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Christie M. Ballantyne, Deepak L. Bhatt, Christopher P. Cannon, Sergio Fazio, Marc S. Sabatine

    Research output: Contribution to journalArticle


    This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.)

    Original languageEnglish (US)
    JournalAmerican Journal of Cardiology
    StateAccepted/In press - Jan 1 2018


    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this